September 7, 2022

Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma

STOCKHOLM — September 7, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hema...
Read more
September 4, 2022

CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

The reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral ai...
Read more
September 2, 2022

Vicore update on the AIR phase 2 trial in idiopathic pulmonary fibrosis

The previously reported February interim analysis will be presented as a late breaker at the ERS congressObservations of continued stabilization and increase in lung capacityA sec...
Read more
August 31, 2022

Emactuzumab designated as an Orphan Medicinal Product in Europe

TGCT is a debilitating disease that often impacts patients in the prime of their lifeDesignation to include both localized and diffuse forms of the disease Dublin, Ireland, 31 ...
Read more
August 29, 2022

Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3

HAMILTON, ON and BOSTON, Aug. 29, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next...
Read more
August 25, 2022

Interim report April – June 2022

Gothenburg, August 25, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2022. Important events during the second quarter In April, ...
Read more
August 19, 2022

Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn

Gothenburg, August 19, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 re...
Read more
August 18, 2022

European Commission approves Oncopeptides’ Pepaxti for the treatment of patients with relapsed refractory multiple myeloma

STOCKHOLM — August 18, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hemato...
Read more
August 18, 2022

Targovax ASA: Second quarter and first half year 2022 results

Oslo, Norway, 18 August 2022 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announce...
Read more
August 17, 2022

Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress

The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF)Interim data have shown stabilization of the disease and an increase i...
Read more